Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Hispanic ethnicity as a moderator of the effects of aerobic and resistance exercise in survivors of breast cancer.

Dieli-Conwright CM, Sweeney FC, Courneya KS, Tripathy D, Sami N, Lee K, Buchanan TA, Spicer D, Bernstein L, Mortimer JE, Demark-Wahnefried W.

Cancer. 2019 Mar 15;125(6):910-920. doi: 10.1002/cncr.31879. Epub 2018 Nov 30.

PMID:
30500981
2.

Aerobic and resistance exercise improves physical fitness, bone health, and quality of life in overweight and obese breast cancer survivors: a randomized controlled trial.

Dieli-Conwright CM, Courneya KS, Demark-Wahnefried W, Sami N, Lee K, Sweeney FC, Stewart C, Buchanan TA, Spicer D, Tripathy D, Bernstein L, Mortimer JE.

Breast Cancer Res. 2018 Oct 19;20(1):124. doi: 10.1186/s13058-018-1051-6.

3.

Body Composition with Dual-Energy X-Ray Absorptiometry and Bioelectrical Impedance Analysis in Breast Cancer Survivors.

Lee K, Sami N, Sweeney FC, Dieli-Conwright CM.

Nutr Clin Pract. 2019 Jun;34(3):421-427. doi: 10.1002/ncp.10194. Epub 2018 Sep 25.

PMID:
30251390
4.

The evolution of clinical trials: Can we address the challenges of the future?

Eichler HG, Sweeney F.

Clin Trials. 2018 Feb;15(1_suppl):27-32. doi: 10.1177/1740774518755058.

PMID:
29452522
5.

Provision of rehabilitation services for children with disabilities living in low- and middle-income countries: a scoping review.

Magnusson D, Sweeney F, Landry M.

Disabil Rehabil. 2019 Apr;41(7):861-868. doi: 10.1080/09638288.2017.1411982. Epub 2017 Dec 7.

PMID:
29212379
6.

Impact of meningitis on intelligence and development: A systematic review and meta-analysis.

Christie D, Rashid H, El-Bashir H, Sweeney F, Shore T, Booy R, Viner RM.

PLoS One. 2017 Aug 24;12(8):e0175024. doi: 10.1371/journal.pone.0175024. eCollection 2017. Review.

7.

Improving public health by improving clinical trial guidelines and their application.

Landray MJ, Bax JJ, Alliot L, Buyse M, Cohen A, Collins R, Hindricks G, James SK, Lane S, Maggioni AP, Meeker-O'Connell A, Olsson G, Pocock SJ, Rawlins M, Sellors J, Shinagawa K, Sipido KR, Smeeth L, Stephens R, Stewart MW, Stough WG, Sweeney F, Van de Werf F, Woods K, Casadei B.

Eur Heart J. 2017 Jun 1;38(21):1632-1637. doi: 10.1093/eurheartj/ehx086.

8.

Direct observation of individual hydrogen atoms at trapping sites in a ferritic steel.

Chen YS, Haley D, Gerstl SS, London AJ, Sweeney F, Wepf RA, Rainforth WM, Bagot PA, Moody MP.

Science. 2017 Mar 17;355(6330):1196-1199. doi: 10.1126/science.aal2418. Epub 2017 Mar 16.

9.

Robust Translation of γ-Secretase Modulator Pharmacology across Preclinical Species and Human Subjects.

Toyn JH, Boy KM, Raybon J, Meredith JE Jr, Robertson AS, Guss V, Hoque N, Sweeney F, Zhuo X, Clarke W, Snow K, Denton RR, Zuev D, Thompson LA, Morrison J, Grace J, Berisha F, Furlong M, Wang JS, Lentz KA, Padmanabha R, Cook L, Wei C, Drexler DM, Macor JE, Albright CF, Gasior M, Olson RE, Hong Q, Soares HD, AbuTarif M, Ahlijanian MK.

J Pharmacol Exp Ther. 2016 Jul;358(1):125-37. doi: 10.1124/jpet.116.232249. Epub 2016 Apr 20.

10.

The γ-Secretase Modulator, BMS-932481, Modulates Aβ Peptides in the Plasma and Cerebrospinal Fluid of Healthy Volunteers.

Soares HD, Gasior M, Toyn JH, Wang JS, Hong Q, Berisha F, Furlong MT, Raybon J, Lentz KA, Sweeney F, Zheng N, Akinsanya B, Berman RM, Thompson LA, Olson RE, Morrison J, Drexler DM, Macor JE, Albright CF, Ahlijanian MK, AbuTarif M.

J Pharmacol Exp Ther. 2016 Jul;358(1):138-50. doi: 10.1124/jpet.116.232256. Epub 2016 Apr 20.

11.

Enhancing clinical evidence by proactively building quality into clinical trials.

Meeker-O'Connell A, Glessner C, Behm M, Mulinde J, Roach N, Sweeney F, Tenaerts P, Landray MJ.

Clin Trials. 2016 Aug;13(4):439-44. doi: 10.1177/1740774516643491. Epub 2016 Apr 20.

12.

Differential roles of GABAB1 subunit isoforms on locomotor responses to acute and repeated administration of cocaine.

Jacobson LH, Sweeney FF, Kaupmann K, O'Leary OF, Gassmann M, Bettler B, Cryan JF.

Behav Brain Res. 2016 Feb 1;298(Pt B):12-6. doi: 10.1016/j.bbr.2015.10.039. Epub 2015 Oct 27.

PMID:
26518330
13.

Biodegradation of the alkaline cellulose degradation products generated during radioactive waste disposal.

Rout SP, Radford J, Laws AP, Sweeney F, Elmekawy A, Gillie LJ, Humphreys PN.

PLoS One. 2014 Sep 30;9(9):e107433. doi: 10.1371/journal.pone.0107433. eCollection 2014.

14.

Structural basis of Rad53 kinase activation by dimerization and activation segment exchange.

Wybenga-Groot LE, Ho CS, Sweeney FD, Ceccarelli DF, McGlade CJ, Durocher D, Sicheri F.

Cell Signal. 2014 Sep;26(9):1825-36. doi: 10.1016/j.cellsig.2014.05.004. Epub 2014 May 9.

PMID:
24815189
15.

Activation but not blockade of GABAB receptors during early-life alters anxiety in adulthood in BALB/c mice.

Sweeney FF, O'Leary OF, Cryan JF.

Neuropharmacology. 2014 Jun;81:303-10. doi: 10.1016/j.neuropharm.2013.08.039. Epub 2013 Sep 17.

PMID:
24050962
16.

European Union Clinical Trials Register: on the way to more transparency of clinical trial data.

Egger GF, Herold R, Rodriguez A, Manent N, Sweeney F, Saint Raymond A.

Expert Rev Clin Pharmacol. 2013 Sep;6(5):457-9. doi: 10.1586/17512433.2013.827404. Epub 2013 Aug 24. No abstract available.

PMID:
23971872
17.

GABAB receptor ligands do not modify conditioned fear responses in BALB/c mice.

Sweeney FF, O'Leary OF, Cryan JF.

Behav Brain Res. 2013 Nov 1;256:151-6. doi: 10.1016/j.bbr.2013.07.035. Epub 2013 Aug 8.

PMID:
23933467
18.

Parents' experiences of support during and after their child's diagnosis of meningococcal disease.

Sweeney F, Viner RM, Booy R, Christie D.

Acta Paediatr. 2013 Mar;102(3):e126-30. doi: 10.1111/apa.12112. Epub 2013 Jan 4.

PMID:
23205710
19.

Quantitative phase contrast optimised cancerous cell differentiation via ptychography.

Claus D, Maiden AM, Zhang F, Sweeney FG, Humphry MJ, Schluesener H, Rodenburg JM.

Opt Express. 2012 Apr 23;20(9):9911-8. doi: 10.1364/OE.20.009911.

PMID:
22535083
20.

An inter-laboratory validation of a real time PCR assay to measure host excretion of bacterial pathogens, particularly of Mycobacterium bovis.

Travis ER, Gaze WH, Pontiroli A, Sweeney FP, Porter D, Mason S, Keeling MJ, Jones RM, Sawyer J, Aranaz A, Rizaldos EC, Cork J, Delahay RJ, Wilson GJ, Hewinson RG, Courtenay O, Wellington EM.

PLoS One. 2011;6(11):e27369. doi: 10.1371/journal.pone.0027369. Epub 2011 Nov 14.

21.

The age of anxiety: role of animal models of anxiolytic action in drug discovery.

Cryan JF, Sweeney FF.

Br J Pharmacol. 2011 Oct;164(4):1129-61. doi: 10.1111/j.1476-5381.2011.01362.x. Review.

22.

An audience with… Fergus Sweeney. Interview by Asher Mullard.

Sweeney F.

Nat Rev Drug Discov. 2011 May;10(5):332. doi: 10.1038/nrd3443. No abstract available.

PMID:
21532555
23.

Pathogen quantitation in complex matrices: a multi-operator comparison of DNA extraction methods with a novel assessment of PCR inhibition.

Pontiroli A, Travis ER, Sweeney FP, Porter D, Gaze WH, Mason S, Hibberd V, Holden J, Courtenay O, Wellington EM.

PLoS One. 2011 Mar 23;6(3):e17916. doi: 10.1371/journal.pone.0017916.

24.

Restraint stress-induced brain activation patterns in two strains of mice differing in their anxiety behaviour.

O'Mahony CM, Sweeney FF, Daly E, Dinan TG, Cryan JF.

Behav Brain Res. 2010 Dec 1;213(2):148-54. doi: 10.1016/j.bbr.2010.04.038. Epub 2010 May 7.

PMID:
20435071
25.

CDC5 inhibits the hyperphosphorylation of the checkpoint kinase Rad53, leading to checkpoint adaptation.

Vidanes GM, Sweeney FD, Galicia S, Cheung S, Doyle JP, Durocher D, Toczyski DP.

PLoS Biol. 2010 Jan 26;8(1):e1000286. doi: 10.1371/journal.pbio.1000286.

26.

Abnormal TDP-43 expression is identified in the neocortex in cases of dementia pugilistica, but is mainly confined to the limbic system when identified in high and moderate stages of Alzheimer's disease.

King A, Sweeney F, Bodi I, Troakes C, Maekawa S, Al-Sarraj S.

Neuropathology. 2010 Aug;30(4):408-19. doi: 10.1111/j.1440-1789.2009.01085.x. Epub 2010 Jan 19.

PMID:
20102526
27.

Clinical trials in developing countries: risk or opportunity?

Saint Raymond A, Sweeney F.

Future Med Chem. 2009 Oct;1(7):1193-5. doi: 10.4155/fmc.09.103. No abstract available.

28.

Performance of an environmental test to detect Mycobacterium bovis infection in badger social groups.

Courtenay O, Reilly LA, Sweeney FP, Macdonald DW, Delahay RJ, Wilson GJ, Cheeseman CL, Keeling MJ, Wellington EM.

Vet Rec. 2007 Dec 15;161(24):817-8. No abstract available.

PMID:
18083981
29.

Orchestration of the DNA-damage response by the RNF8 ubiquitin ligase.

Kolas NK, Chapman JR, Nakada S, Ylanko J, Chahwan R, Sweeney FD, Panier S, Mendez M, Wildenhain J, Thomson TM, Pelletier L, Jackson SP, Durocher D.

Science. 2007 Dec 7;318(5856):1637-40. Epub 2007 Nov 15.

30.

Environmental monitoring of Mycobacterium bovis in badger feces and badger sett soil by real-time PCR, as confirmed by immunofluorescence, immunocapture, and cultivation.

Sweeney FP, Courtenay O, Hibberd V, Hewinson RG, Reilly LA, Gaze WH, Wellington EM.

Appl Environ Microbiol. 2007 Nov;73(22):7471-3. Epub 2007 Sep 28.

31.

A screen for suppressors of gross chromosomal rearrangements identifies a conserved role for PLP in preventing DNA lesions.

Kanellis P, Gagliardi M, Banath JP, Szilard RK, Nakada S, Galicia S, Sweeney FD, Cabelof DC, Olive PL, Durocher D.

PLoS Genet. 2007 Aug;3(8):e134.

32.

Is Mycobacterium bovis in the environment important for the persistence of bovine tuberculosis?

Courtenay O, Reilly LA, Sweeney FP, Hibberd V, Bryan S, Ul-Hassan A, Newman C, Macdonald DW, Delahay RJ, Wilson GJ, Wellington EM.

Biol Lett. 2006 Sep 22;2(3):460-2.

33.

Many-beam dynamical simulation of electron backscatter diffraction patterns.

Winkelmann A, Trager-Cowan C, Sweeney F, Day AP, Parbrook P.

Ultramicroscopy. 2007 Apr-May;107(4-5):414-21. Epub 2006 Nov 13.

PMID:
17126489
34.

Immunomagnetic recovery of Mycobacterium bovis from naturally infected environmental samples.

Sweeney FP, Courtenay O, Ul-Hassan A, Hibberd V, Reilly LA, Wellington EM.

Lett Appl Microbiol. 2006 Oct;43(4):364-9.

35.

Structure-activity relationships of triazolopyridine oxazole p38 inhibitors: identification of candidates for clinical development.

McClure KF, Letavic MA, Kalgutkar AS, Gabel CA, Audoly L, Barberia JT, Braganza JF, Carter D, Carty TJ, Cortina SR, Dombroski MA, Donahue KM, Elliott NC, Gibbons CP, Jordan CK, Kuperman AV, Labasi JM, Laliberte RE, McCoy JM, Naiman BM, Nelson KL, Nguyen HT, Peese KM, Sweeney FJ, Taylor TJ, Trebino CE, Abramov YA, Laird ER, Volberg WA, Zhou J, Bach J, Lombardo F.

Bioorg Med Chem Lett. 2006 Aug 15;16(16):4339-44. Epub 2006 Jun 12.

PMID:
16759861
36.

Theoretical and experimental design of atypical kinase inhibitors: application to p38 MAP kinase.

McClure KF, Abramov YA, Laird ER, Barberia JT, Cai W, Carty TJ, Cortina SR, Danley DE, Dipesa AJ, Donahue KM, Dombroski MA, Elliott NC, Gabel CA, Han S, Hynes TR, Lemotte PK, Mansour MN, Marr ES, Letavic MA, Pandit J, Ripin DB, Sweeney FJ, Tan D, Tao Y.

J Med Chem. 2005 Sep 8;48(18):5728-37.

PMID:
16134941
37.

Saccharomyces cerevisiae Rad9 acts as a Mec1 adaptor to allow Rad53 activation.

Sweeney FD, Yang F, Chi A, Shabanowitz J, Hunt DF, Durocher D.

Curr Biol. 2005 Aug 9;15(15):1364-75.

38.

Discovery of 3-OH-3-methylpipecolic hydroxamates: potent orally active inhibitors of aggrecanase and MMP-13.

Noe MC, Natarajan V, Snow SL, Wolf-Gouveia LA, Mitchell PG, Lopresti-Morrow L, Reeves LM, Yocum SA, Otterness I, Bliven MA, Carty TJ, Barberia JT, Sweeney FJ, Liras JL, Vaughn M.

Bioorg Med Chem Lett. 2005 Jul 15;15(14):3385-8.

PMID:
15953722
39.

Discovery of 3,3-dimethyl-5-hydroxypipecolic hydroxamate-based inhibitors of aggrecanase and MMP-13.

Noe MC, Natarajan V, Snow SL, Mitchell PG, Lopresti-Morrow L, Reeves LM, Yocum SA, Carty TJ, Barberia JA, Sweeney FJ, Liras JL, Vaughn M, Hardink JR, Hawkins JM, Tokar C.

Bioorg Med Chem Lett. 2005 Jun 2;15(11):2808-11.

PMID:
15911259
40.

Benzimidazolone p38 inhibitors.

Dombroski MA, Letavic MA, McClure KF, Barberia JT, Carty TJ, Cortina SR, Csiki C, Dipesa AJ, Elliott NC, Gabel CA, Jordan CK, Labasi JM, Martin WH, Peese KM, Stock IA, Svensson L, Sweeney FJ, Yu CH.

Bioorg Med Chem Lett. 2004 Feb 23;14(4):919-23.

PMID:
15012994
41.

Synthesis and biological activity of piperazine-based dual MMP-13 and TNF-alpha converting enzyme inhibitors.

Letavic MA, Barberia JT, Carty TJ, Hardink JR, Liras J, Lopresti-Morrow LL, Mitchell PG, Noe MC, Reeves LM, Snow SL, Stam EJ, Sweeney FJ, Vaughn ML, Yu CH.

Bioorg Med Chem Lett. 2003 Oct 6;13(19):3243-6.

PMID:
12951101
42.

Inhibition of IL-1beta-dependent prostaglandin E2 release by antisense microsomal prostaglandin E synthase 1 oligonucleotides in A549 cells.

Sweeney FJ, Wachtmann TS, Eskra JD, Verdries KA, Lambalot RH, Carty TJ, Perez JR, Audoly LP.

Mol Cell Endocrinol. 2003 Jul 31;205(1-2):151-7.

PMID:
12890577
43.

Characterization of nitride thin films by electron backscatter diffraction.

Trager-Cowan C, Sweeney F, Hastie J, Manson-Smith SK, Cowan DA, McColl D, Mohammed A, O'Donnell KP, Zubia D, Hersee SD, Foxon CT, Harrison I, Novikov SV.

J Microsc. 2002 Mar;205(Pt 3):226-30.

44.

Synthesis and biological activity of selective pipecolic acid-based TNF-alpha converting enzyme (TACE) inhibitors.

Letavic MA, Axt MZ, Barberia JT, Carty TJ, Danley DE, Geoghegan KF, Halim NS, Hoth LR, Kamath AV, Laird ER, Lopresti-Morrow LL, McClure KF, Mitchell PG, Natarajan V, Noe MC, Pandit J, Reeves L, Schulte GK, Snow SL, Sweeney FJ, Tan DH, Yu CH.

Bioorg Med Chem Lett. 2002 May 20;12(10):1387-90.

PMID:
11992783
45.

The 7.5-A electron density and spectroscopic properties of a novel low-light B800 LH2 from Rhodopseudomonas palustris.

Hartigan N, Tharia HA, Sweeney F, Lawless AM, Papiz MZ.

Biophys J. 2002 Feb;82(2):963-77.

46.

Histology and tissue chemistry of tidemark separation in hamsters.

Otterness IG, Chang M, Burkhardt JE, Sweeney FJ, Milici AJ.

Vet Pathol. 1999 Mar;36(2):138-45.

PMID:
10098642
47.

Tamoxifen for the prevention of breast cancer in high-risk women.

Sweeney FW, Newton WP.

J Fam Pract. 1999 Feb;48(2):90-1. No abstract available.

PMID:
10037532
48.

Tenidap inhibits 5-lipoxygenase product formation in vitro, but this activity is not observed in three animal models.

Carty TJ, Sweeney FJ, Griffiths RJ, Eskra JD, Ernest MJ, Pillar JS, Cheng JD, Loose LD, Joseph PA, Pazoles PP, Moore PF, Nagahisa A, Murase S, Kadin SB.

Inflamm Res. 1997 May;46(5):168-79.

PMID:
9197987
50.

Tenidap, a structurally novel drug for the treatment of arthritis: antiinflammatory and analgesic properties.

Moore PF, Larson DL, Otterness IG, Weissman A, Kadin SB, Sweeney FJ, Eskra JD, Nagahisa A, Sakakibara M, Carty TJ.

Inflamm Res. 1996 Feb;45(2):54-61.

PMID:
8907585

Supplemental Content

Loading ...
Support Center